Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZVS101e in Bietti Crystalline Corneoretinal Dystrophy
NCT07653971Not yet recruiting
- Sponsor
- CHIGENOVO
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Open-label, single-arm trial of ZVS101e in Bietti crystalline dystrophy (BCD), sponsored by CHIGENOVO. Primary endpoints: Best Corrected Visual Acuity at 52 weeks and Adverse Events and Serious Adverse Events at 52 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ZVS101e
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT07653971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653971.